News & Events about Meiragtx Holdings Plc.
LONDONandNEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdingsplc(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced two abstract presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting. The first ...
- Announced positive clinical data from AQUAx AAV-hAQP1 Phase 1 trial for treatment of Grade 2/3 Radiation-Induced Xerostomia in December 2022 - Announced positive top-line data from the MGT009 Phase 1/2 clinical study demonstrating safety and improvement in multiple domains of vision in X-linked ...
Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial of botaretigene sparoparvovec in XLRP, which is actively dosing patientsLONDONandNEW YORK, Oct. 01, 2022 (GLOBE NEWSWIRE) -- MeiraGTx ...
--Manufacturing facilities built to accelerate development and delivery of advanced medicines to patients using state-of-the-art technology at scale, with quality appropriate for commercialization --Site reflects MeiraGTxs unique, end-to-end approach to gene therapy manufacturing to expedite ...
-- Recent Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) -- Financing Secured by Manufacturing Facilities Extends Cash Runway to Fourth Quarter 2024 LONDONandNEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE...